Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.09
ULGX's Cash to Debt is ranked lower than
120% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ULGX: 0.09 )
Ranked among companies with meaningful Cash to Debt only.
ULGX' s 10-Year Cash to Debt Range
Min: 0.09  Med: 10000.00 Max: No Debt
Current: 0.09
Equity to Asset -1.61
ULGX's Equity to Asset is ranked lower than
136% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ULGX: -1.61 )
Ranked among companies with meaningful Equity to Asset only.
ULGX' s 10-Year Equity to Asset Range
Min: -1.61  Med: 0.84 Max: 0.96
Current: -1.61
-1.61
0.96
F-Score: 3
Z-Score: -36.39
M-Score: -7.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -32.29
ULGX's Operating margin (%) is ranked lower than
127% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. ULGX: -32.29 )
Ranked among companies with meaningful Operating margin (%) only.
ULGX' s 10-Year Operating margin (%) Range
Min: -1950  Med: -38.35 Max: 12.1
Current: -32.29
-1950
12.1
Net-margin (%) -38.29
ULGX's Net-margin (%) is ranked lower than
127% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. ULGX: -38.29 )
Ranked among companies with meaningful Net-margin (%) only.
ULGX' s 10-Year Net-margin (%) Range
Min: -1900  Med: -34.48 Max: 21.22
Current: -38.29
-1900
21.22
ROA (%) -75.67
ULGX's ROA (%) is ranked lower than
119% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. ULGX: -75.67 )
Ranked among companies with meaningful ROA (%) only.
ULGX' s 10-Year ROA (%) Range
Min: -83.63  Med: -27.48 Max: 13.24
Current: -75.67
-83.63
13.24
ROC (Joel Greenblatt) (%) -978.93
ULGX's ROC (Joel Greenblatt) (%) is ranked lower than
121% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 3.52 vs. ULGX: -978.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ULGX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -577.5  Med: -111.51 Max: 231.06
Current: -978.93
-577.5
231.06
Revenue Growth (3Y)(%) -8.00
ULGX's Revenue Growth (3Y)(%) is ranked lower than
191% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. ULGX: -8.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ULGX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -20.9  Med: 2.95 Max: 108
Current: -8
-20.9
108
EBITDA Growth (3Y)(%) 10.90
ULGX's EBITDA Growth (3Y)(%) is ranked lower than
219% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. ULGX: 10.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ULGX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -80.1  Med: -26.20 Max: 17
Current: 10.9
-80.1
17
EPS Growth (3Y)(%) 11.50
ULGX's EPS Growth (3Y)(%) is ranked lower than
221% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. ULGX: 11.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ULGX' s 10-Year EPS Growth (3Y)(%) Range
Min: -54.1  Med: -5.45 Max: 11.9
Current: 11.5
-54.1
11.9
» ULGX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ULGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 0.15
ULGX's P/S is ranked lower than
135% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. ULGX: 0.15 )
Ranked among companies with meaningful P/S only.
ULGX' s 10-Year P/S Range
Min: 0.07  Med: 1.09 Max: 5.96
Current: 0.15
0.07
5.96
Current Ratio 0.56
ULGX's Current Ratio is ranked lower than
123% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 2.44 vs. ULGX: 0.56 )
Ranked among companies with meaningful Current Ratio only.
ULGX' s 10-Year Current Ratio Range
Min: 0.56  Med: 4.40 Max: 24.53
Current: 0.56
0.56
24.53
Quick Ratio 0.34
ULGX's Quick Ratio is ranked lower than
123% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. ULGX: 0.34 )
Ranked among companies with meaningful Quick Ratio only.
ULGX' s 10-Year Quick Ratio Range
Min: 0.34  Med: 3.71 Max: 24.29
Current: 0.34
0.34
24.29
Days Inventory 76.48
ULGX's Days Inventory is ranked lower than
136% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 129.48 vs. ULGX: 76.48 )
Ranked among companies with meaningful Days Inventory only.
ULGX' s 10-Year Days Inventory Range
Min: 54.36  Med: 96.21 Max: 277.9
Current: 76.48
54.36
277.9
Days Sales Outstanding 41.68
ULGX's Days Sales Outstanding is ranked lower than
140% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 69.92 vs. ULGX: 41.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
ULGX' s 10-Year Days Sales Outstanding Range
Min: 34.05  Med: 46.42 Max: 130.36
Current: 41.68
34.05
130.36

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.06
ULGX's Price/Median PS Value is ranked lower than
145% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. ULGX: 0.06 )
Ranked among companies with meaningful Price/Median PS Value only.
ULGX' s 10-Year Price/Median PS Value Range
Min: 0.11  Med: 1.86 Max: 150
Current: 0.06
0.11
150
Earnings Yield (Greenblatt) (%) -60.54
ULGX's Earnings Yield (Greenblatt) (%) is ranked lower than
124% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. ULGX: -60.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ULGX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.3  Med: 4.40 Max: 3169.7
Current: -60.54
1.3
3169.7

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Urologix Inc was incorporated in Minnesota. The Company develops, manufactures, and markets non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from non-cancerous prostate enlargement also known as benign prostatic hyperplasia (BPH). These therapies use proprietary technology in the treatment of BPH, a disease that affects more than 30 million men worldwide and is the common prostate problem for men over 50. It markets both the Cooled ThermoTherapy (CTT) product line and the Prostiva Radio Frequency (RF) Therapy System. It acquired the license to the Prostiva RF Therapy System in September 2011. These two technologies are designed to be used by urologists in their offices without placing their patients under general anesthesia. CTT uses a flexible catheter to deliver targeted microwave energy combined with a unique cooling mechanism that protects healthy urethral tissue and enhances patient comfort to provide safe, effective, lasting relief from BPH voiding symptoms by the thermal ablation of hyperplastic prostatic tissue surrounding the urethra. The proprietary Prostiva RF Therapy System delivers radio frequency energy directly into the prostate through the use of insulated electrodes deployed from a transurethral scope, ablating targeted prostatic tissue under the direct visualization of the urologist. These focal ablations reduce constriction of the urethra, thereby relieving BPH voiding symptoms. These two proven technologies have slightly different, yet complementary, patient indications and providing them to its urologist customers enables them to treat a various patients in their office. Both domestic and international government regulation significantly affects the research and development, manufacturing and marketing of its products.
» More Articles for ULGX

Headlines

Articles On GuruFocus.com
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 5,200 Shares Feb 01 2011 
Urologix Inc. Reports Operating Results (10-K) Sep 17 2010 
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 16,900 Shares Dec 08 2009 
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 3,100 Shares Dec 07 2009 
Urologix Inc. Reports Operating Results (10-K) Sep 21 2009 
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 1,870 Shares Sep 03 2009 
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 1,635 Shares Aug 31 2009 
Urologix Reports Fiscal 2009 Results Including Sequential Growth in Fourth Quarter Fiscal Year 2009 Aug 25 2009 
Urologix to Host Its Fiscal Year 2009 and Fourth Quarter Conference Call Aug 19 2009 
Urologix Inc. (ULGX) CEO Stryker Jr Warren buys 1,495 Shares May 29 2009 

More From Other Websites
Edited Transcript of ULGX earnings conference call or presentation 12-May-15 9:00pm GMT Jul 16 2015
UROLOGIX INC Files SEC form 8-K, Other Events Jul 10 2015
Urologix Announces SEC Deregistration Jul 09 2015
UROLOGIX INC Financials May 27 2015
UROLOGIX INC Files SEC form 10-Q, Quarterly Report May 14 2015
UROLOGIX INC Files SEC form 8-K, Results of Operations and Financial Condition May 13 2015
Urologix Inc Earnings Call scheduled for 5:00 pm ET today May 12 2015
UROLOGIX INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Mar 23 2015
UROLOGIX INC Files SEC form 10-Q, Quarterly Report Feb 13 2015
UROLOGIX INC Files SEC form 8-K, Results of Operations and Financial Condition Feb 06 2015
UROLOGIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events Jan 12 2015
UROLOGIX INC Files SEC form 10-Q, Quarterly Report Nov 13 2014
UROLOGIX INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Nov 10 2014
UROLOGIX INC Files SEC form 8-K, Results of Operations and Financial Condition Nov 05 2014
UROLOGIX INC Files SEC form 8-K, Change in Directors or Principal Officers Sep 25 2014
UROLOGIX INC Files SEC form 10-K, Annual Report Sep 19 2014
UROLOGIX INC Files SEC form 8-K, Results of Operations and Financial Condition Aug 20 2014
UROLOGIX INC Files SEC form 8-K, Change in Directors or Principal Officers Aug 19 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK